Background: The vaccine against human papillomavirus (HPV) was created to abrogate the risk that the virus presents for the development of cervical cancers. The prevalence of HPV infection among healthy individuals is significant (20%). We performed a review of the literature published in the period from 2008 to 2012 regarding the use of the vaccine against HPV specifically in adolescents. Methods: The articles were selected from a search of the PubMed database with the key words ''vaccine'', ''HPV'' and ''adolescent''. This search identified 576 articles; based on readings of the titles and abstracts, the list of included article was reduced to 42. Results: We observed that the majority of authors are in favor of the vaccine for adolescents particularly females. Conclusion: Recommending the use of the HPV vaccine and other vaccines represents an attempt to broaden the reach of these vaccines among both sexes of the adolescent population. Vaccination is a strategy for the prevention of pre-cancerous lesions in the genital and oropharyngeal regions.
Introduction
World estimates have indicated that 20% of healthy individuals are contaminated with the human papillomavirus (HPV) and that this virus is primarily transmitted through sexual contact, although direct contact with contaminated objects can also lead to infection. HPV is related to the development of approximately 98% of the cases of cervical cancers; thus, infection with the virus is a public health problem, and the prevention of such infections is mandatory [1] [2] [3] [4] .
The prophylactic vaccine against the HPV L1 viral particle is an effective method for the prevention of the infection of naïve women and HPV-negative persons; therefore, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention have recommended the universal administration of the three doses of quadrivalent or bivalent HPV vaccine to girls of 11-12 years of age, although the minimum recommended age varies with geographic region [2, 5, 6] .
Based on a cost-benefit analysis, the ACIP recommended the administration of the anti-HPV virus to 11-or 12-year-old girls for the prevention of genital warts, anal cancer and possibly cancers of the head and neck because the vaccine is considered to be highly effective and provides protection against the four types of HPV [7, 8] .
Parents' interest vaccinating their children and the interest of adults (up to 26 years of age) in getting vaccinated are directly related to the relevant party's knowledge of the efficacy of the vaccine, and studies have demonstrated that the acceptance of the vaccine is greater people are aware of the associations between some types of cancer and HPV [4, 9] .
To increase the knowledge of the use of the prophylactic HPV vaccine in adolescents, we performed a review of the published literature that broadly discussed this subject in the period from January 2008 to August 2012.
Methods

Search strategy
The PubMed database was searched for relevant articles published in English from 2008 to August 2012. The studies were grouped according to whether they evaluated the indications for administration of the HPV vaccine to adolescents. A broad search strategy was pursued to capture the relevant studies of the HPV vaccine and the indications for the HPV vaccine in adolescents. The keywords 'HPV', 'vaccine' and 'adolescent' were used. Data from longitudinal studies were included, and the references of the retrieved articles were analyzed to identify additional relevant studies.
Study selection
The studies were selected based on their titles and abstracts, and articles without available abstracts and full-texts were excluded. Agreement between the readers was determined statistically, and any conflicts were resolved by discussion or the analysis of a third reader (GIM). This procedure was applied at all selection stages. The full-text articles were evaluated by the readers using a pilot-test form.
Inclusion/exclusion criteria
The inclusion criteria were the following: indications for the administration of the HPV vaccine to children and adolescents regardless of age group and sex, and scientific research projects. Simple and systematic reviews were also included.
Studies with the following main themes were excluded: acceptance, awareness and applicability of the prophylactic HPV vaccine; efficacy of the vaccine; costs and benefits of the vaccine; barriers to the implementation of the vaccine; effect of the vaccine on society; estimates of the immunized population; general concepts of the vaccine; opinions of vaccinated persons; perspectives on the vaccine in prevention; most frequent types of HPV; use of the three doses in clinical routines; simultaneous use of vaccines, including the HPV vaccines; other languages; ethical and legal questions regarding the use of the vaccine; vaccination strategies; sexual behavior after vaccination; perspectives for the control of cancer; intentions of men to have themselves vaccinated; expression of genes and productions of antibodies; and free-ofcharge distribution of vaccines by clinics. When necessary, the exclusion criteria were reviewed, and the abstracts were re-assessed until a complete definition of the exclusion criteria was determined.
Outcomes and variables
The following information was extracted from each included study: year of publication; age-range of those for whom the vaccine was indicated; sex indicated to receive the vaccine; recommendations regarding HPV vaccination of physicians; and the availability of the vaccine to society.
Results
Study sample
The search detailed above resulted in the identification of 576 articles. After reading the titles and abstracts, 534 articles were excluded because they focused on other subjects related to the vaccine (Table 1) . Thus, our review encompassed a total of only 42 articles. 
Recommendations of physicians regarding HPV vaccination
Of the 42 included articles, five addressed recommendations regarding the prophylactic use of the HPV vaccine (bivalent or quadrivalent) by physicians ( Table 2 ). Most of the physicians favored the use of the vaccine. However, many clinical opportunities were lost. Possible reasons for these missed opportunities included the short time of each consultation, forgetfulness on the part of doctor, and the population's absence of interest in the HPV vaccine due to lack of information.
Recommendation regarding HPV vaccination for females and males
The 42 included articles were in favor of the prophylactic use of the HPV vaccine; these articles particularly emphasized the potential benefits for the prevention of cervical cancers. The percentages of articles that recommended the use of the Research conducted in the USA to verify the number of girls (11-12 years) who received prophylactic HPV vaccine, disclosed that few girls were immunized. The immunization strategy proposed is to carry out annual visits for preventive care and administration of vaccines jointly in this age group. [35] Female Questions the use HPV vaccine for all
Male -
The article approaches the topic of vaccination as a means that could be applied to the entire population, irrespective of age, sexual habits, sex and systemic condition. However, it makes it clear that in order to adopt this measure, it would be necessary to await the researches on the efficacy and safety of the vaccine for each population. [42] Female -Points out the importance of elucidation as regards the benefits of the vaccine for the male sex, so that there were be greater HPV vaccine adherence by this sex.
Male Support the vaccine for males. O'Connor (2009) [43] Female -The use of prophylactic HPV vaccine in the male sex, in addition to being of indirect benefit to women, prevents important lesions related to HPV, irrespective of sexual habits. Male Until age 26 Hull and Caplan (2009) [44] Female -Reinforces that the vaccination policy is still focused on the female sex, however, it should be offered to and encouraged for both sexes, making it more effective because of immunizing all possible carriers of the virus.
Male
Suggest the vaccine, but not for specific age HPV vaccine by females beginning at the lowest ages of 8-to 14-years-old was 11.9%, and 50% of the articles recommended the use of the HPV vaccine by females in the highest age group of 9-to 26-years-old. Other age groups were mentioned by seven articles, but these age groups did not vary from the age range of 8-to 26-years-old. Six articles mentioned indications for the use of the vaccine among males only, two articles did not specify an age range for the use of the vaccine, and only a single article emphasized the indication for older women (>26 years). However, other articles also suggested this possibility (Table 2) . A similar pattern was observed regarding the recommendations for males; 9.5% of the articles recommended the HPV vaccine for boys aged 9-to 15-years-old, and 30.9% of the articles recommend the vaccine for boys aged 9-26 years (Table 2) . Seventeen articles did not mention the indication for the use of the vaccine by males, six articles indicated the vaccine without specifying an age group, and only a single article indicated another age group (11-17 years) . One article adopted a position against the prophylactic use of the HPV vaccine by males ( Table 2) .
Availability of the vaccine to society
Many countries in which the authorities are convinced of the safety and efficacy of the prophylactic use of the HPV vaccine are financing the administration of the vaccine to adolescents because these authorities understand that vaccination represents a preventive strategy with a favorable cost-benefit ratio. Table 3 presents important data regarding the vaccination policies of several countries, including the adopted vaccination system, the age of the target population, the type of vaccine applied (i.e., bivalent or quadrivalent) and the year in which the vaccination program began. We observed that 75% (6/8) of the countries adopted programs of routine vaccination of 12-year-old female adolescents, and only two countries opted for the bivalent rather than the quadrivalent vaccination (Table 3) .
Discussion
The main target populations of national immunization programs are adolescent girls regardless of whether they have initiated sexual activity; however, it is probable that many adult, sexually active women wish to receive the vaccine for their individual benefit. Therefore, Wright et al. [11] considered the use of the vaccines to be acceptable in modern clinical practice because these vaccines are immunogenic and safe for use in sexually active women. In Australia, young adolescents (10-17 years) are vaccinated through a project that is carried out in schools, and Australia is the first country to provide the vaccine via a public health program [12, 13] . Many countries, including Brazil, offer prophylactic HPV vaccine to females, primarily those 12-to 13-years-old. In Brazil, a vaccination program for 11-to 13-year-old girls provided through the Sistema Único de Saúde (SUS) national health system was approved, and the campaign was scheduled to begin in March 2014 [10, 14] . Studies have evaluated the recommendation that the vaccine be administered by physicians (i.e., general clinicians, pediatricians and gynecologists), and these studies have reported that a minority of these physicians provided their patients with guidance. This finding indicates that innumerable clinical opportunities for vaccinations against HPV have been lost [15, 16] . In the USA, despite the existence of national guidelines recommending the vaccine for 11-to 26-year-old women, the proportions of physicians who indicate to their patients that they always recommend the vaccine ranges from 25.8% and 74.5% depending on the age range of the patients and the specialties of the physicians [17] . However, in another study that analyzed the indications for the use of the vaccine in men, variation in the recommendations for the use of the vaccine also occurred with age; the vaccine was indicated for 11-to 12-(63.9%), 13-to 18-(93.4%) and 19-to 26-(92.7%) year-old males. Therefore, this medical recommendation is an important and consistent factor for use of the vaccine [16, 17] .
In India, it has been observed that doctors do not doubt the efficacy of the vaccine; therefore, the lack of time during consultations has been found to be the main justification for the non-indication of the vaccine. These doctors were required to prioritize other subjects during consultations or to discuss mandatory vaccines [18] . The author of the study explained that it is necessary for gynecologists and obstetricians to explain the importance of the vaccine to women, not only to encourage them to be vaccinated but also so that those women will have their future children vaccinated because women generally care for the health of their families [19] . Doctors believe that investments in campaigns about the importance of the HPV vaccine would make patients themselves seek vaccination [18] .
A large portion of the authors indicated vaccination for women from 11 to 26 years of age who are not yet sexually active; i.e., those without previous exposure to the virus [3, 6, [20] [21] [22] [23] [24] [25] [26] [27] [28] . However, Borsatto [29] indicated vaccination for all women aged 9-26 years regardless of sexual activity, and others authors, such as Heideman et al. [30] , included indications for older women based on the perspective that the vaccine is a safe and effective investment [24, 31] . The quadrivalent vaccine (HPV4; Gardasil; Merck & Co, Inc., Whitehouse Station, NJ) is contraindicated for persons with histories of immediate hypersensitivity to yeast and pregnant women [32] .
Despite the concern regarding the vaccination of girls who have not initiated sexual activity, i.e., frequently children (9 years), authors believe that the administration of the vaccine at an early age might reduce the immunity offered by the vaccine because it is used well before the phase of high levels of exposure to HPV infection [30] , which frequently occurs among 14-to 16-year-old girls; thus, the vaccine is needed for this latter age group [33] . Another target population for vaccination is young primiparous women (15-24 years of age) among whom the prevalence of HPV in the cervical region is high. In one study group, 58.5% (176/301) of such women were HPV-positive, and 13% carried oncogenic types of HPV (i.e., HPV-16 and HPV-18). This group of women is considered to be at high risk for the development of cervical cancer; therefore, vaccination is proposed to these women during the post-natal consultation to prevent infections with the oncogenic types of HPV [34] .
The vaccine might prevent approximately 70% of the cases of cancer of the uterus and is thus considered a means of eliminating one of the most worrying female diseases and a disease with a high incidence in India [5, 21] . Thus, some authors have been encouraged to develop new research programs regarding the creation of effective vaccines for women who have initiated sexual activity, those who are infected by the virus, and for immunosuppressed patients [20, 35] . Others believe that infection prevention programs for older women must be of a different type because vaccination programs are no longer economically feasible for these women because the efficacies of such programs have not been proven in clinical trials, and the virus is not highly prevalent in this age group [23, 36] .
Regarding males, although Nadal and Nadal [3] does not agree about the benefits of the vaccine for males, in the USA, a recommendation for the prophylactic use of the HPV vaccine by men between the ages of 9 and 26 years was issued, but one year after this recommendation was issued, the rate of vaccination among males of this age group was minimal (2%). This finding indicates the need for strategies to increase the use of the vaccine by this population; such strategies should include explanations about the disease, how it also affects men, how it can be prevented and how the risk to sexual partners can be minimized [37] [38] [39] [40] [41] [42] [43] [44] [45] . Currently, the ACIP states that the HPV vaccine must be administered to men between from 11-to 21-years-old and to men from 22-to 26-years-old who maintain sexual relationships with other men or are HIV-positive [46] . HPV-16 is the most frequent type of infection in men irrespective of age; therefore further studies are needed to determine the best age group for the vaccination of the males, although some have already stated that the appropriate age is the beginning of adolescence (10-15 years of age) [30, 47] . In Australia, despite the belief that the vaccination of men would benefit to the population, there is still no program that finances the vaccination of men, and the author of the relevant study believes that it is not possible to vaccinate the majority of the male population without financing from the government [48] .
Thus, recommendations in favor of the prophylactic uses of the HPV vaccine and other vaccines have made these vaccines more accessible to both sexes of the adolescent populations, and such recommendations represent a strategy for the prevention of pre-cancerous lesions in the genital and oropharyngeal regions [49, 50] .
Conclusion
Despite the small divergences regarding the best indications for the use of the HPV vaccine according to age, sex and sexual habits, all of the reviewed scientific articles maintained that the vaccine is an effective means of prevention even when its use is restricted to a specific section of the population. The continuous study of articles is extremely important for our understanding of the properties of the vaccine and the benefits it provides to certain population groups, particularly those groups that are not targets for this immunization.
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